Sunshine BiopharmaSBFM +1.87%34 Days Payable is 83.16 as of Mar. 2026, which is 50% below its 10-year median of 165.34. GuruFocus rates SBFM with a GF Score™ of 34/100 and a GF Value™ of $7.10 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 920 Drug Manufacturers companies, Sunshine Biopharma ranks worse than 55.22% on this metric.
The historical rank and industry rank for Sunshine Biopharma's Days Payable or its related term are showing as below:
SBFM'
s Days Payable Range Over the Past 10 Years
Min: 61.29 Med: 165.34 Max: 3533.86
Current: 82.03
During the past 13 years, Sunshine Biopharma's highest Days Payable was 3533.86. The lowest was 61.29. And the median was 165.34.
SBFM's Days Payable is ranked worse than 55.22% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs SBFM: 82.03
Sunshine Biopharma's Days Payable
increased
from Mar. 2025 (78.13) to Mar. 2026 (83.16).
It may suggest that Sunshine Biopharmadelayed paying its suppliers.
Sunshine Biopharma Days Payable Related Terms
Sunshine Biopharma Days Payable Historical Data
* Premium members only.
The historical data trend for Sunshine Biopharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Biopharma Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Sunshine Biopharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sunshine Biopharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Biopharma (SBFM) has a Days Payable of 83.16 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sunshine Biopharma and its competitors. This is 50% below median its historical median of 165.34. Over the past decade, Sunshine Biopharma's Days Payable has ranged from 61.29 to 3,533.86. According to the industry distribution chart, Sunshine Biopharma ranks #508 out of 920 companies in the Drug Manufacturers industry, placing it in the top 55.2%.
Is Sunshine Biopharma's Days Payable too high?
Sunshine Biopharma's current Days Payable of 83.16 is 50% below median its 10-year median of 165.34. Over the past 10 years, this metric has ranged from a low of 61.29 to a high of 3,533.86. The Drug Manufacturers industry median Days Payable is 90.84. Sunshine Biopharma's value of 83.16 is 8.4% below this industry median. Based on the distribution chart, Sunshine Biopharma ranks #508 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sunshine Biopharma has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Biopharma's Days Payable compare to PRFX and CTTH?
According to the Drug Manufacturers industry distribution chart, Sunshine Biopharma ranks #508 out of 920 companies for Days Payable. This places Sunshine Biopharma in the lower half of its industry. The industry median Days Payable is 90.84. Sunshine Biopharma's value of 83.16 is 8.4% below this benchmark. Historically, Sunshine Biopharma's own Days Payable has ranged from 61.29 to 3,533.86 over the past decade. While the company's 10-year median is 165.34 vs. the industry median of 90.84, Sunshine Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunshine Biopharma's current Days Payable of 83.16 is 8.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sunshine Biopharma and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Biopharma's current Days Payable is 83.16, which is 50% below median its own 10-year median of 165.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Biopharma (SBFM) is currently considered Possible Value Trap. The stock's GF Value™ is $7.10, compared to a current price of $2.17 — trading 69.4% below its estimated fair value. The current Days Payable is 83.16, which is 50% below median its 10-year median of 165.34 and 8.4% below the Drug Manufacturers industry median of 90.84. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sunshine Biopharma (SBFM), the current Days Payable is 83.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunshine Biopharma (SBFM) Overvalued in 2026?
Based on GuruFocus' analysis, Sunshine Biopharma stock appears to be undervalued.
The current stock price of $2.17 is trading 69.4% below its estimated GF Value™ of $7.10.
GuruFocus considers Sunshine Biopharma to be Possible Value Trap.
Key valuation signals for SBFM:
Days Payable: 83.16 (50% below median its 10-year median of 165.34)
GF Value™: $7.10 vs. price of $2.17 (69.4% below fair value)
Industry Position: 8.4% below the Drug Manufacturers median (#508 of 920)
No single metric tells the full story. See the SBFM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score
Get the complete analysis for SBFM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBFM has been successfully added to your 
